| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3190749 | Annals of Allergy, Asthma & Immunology | 2016 | 8 Pages |
Abstract
SCIT-related fatality rates may be decreasing, but continued vigilance regarding modifiable risk factors, including careful patient selection, is needed. Dose adjustment during pollen seasons for highly sensitive patients may reduce risks. Potential risk for SRs from off-label SLIT exists.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Tolly G. MD, MS, Gary M. MD, MS, Karen BS, David I. MD,